01413nam a2200277 4500 ESSALUD 20260821102447.0 ta t pe ||||| |||| 00| 0 spa d BMG eng Haffajee, Rebecca L. Autor 54222 Marijuana Rescheduling — A Game Changer for Research? páginas: 729-731 On April 22, 2026, the U.S. acting attorney general issued a final rule immediately reclassifying state-licensed medical marijuana products and future Food and Drug Administration (FDA)–approved marijuana products under Schedule III of the Controlled Substances Act. Medical marijuana (cannabis containing ≥0.3% tetrahydrocannabinol), now legal in 40 states, three territories, and the District of Columbia, was previously federally designated as a Schedule I drug — the category of drugs that are the most tightly controlled. MEDICAMENTOS, DISPOSITIVOS Y LA FDA 54223 HEMATOLOGÍA 7422 ONCOLOGÍA GENERAL 54224 DOLOR TRATAMIENTOS EN ONCOLOGÍA 53734 DERECHO SANITARIO 48689 Mikos, Robert A. 54225 Cooper, Ziva D. 54226 22717 22650 Massachusetts NEJM Group NEJM12 The New England Journal of Medicine ESSALUD 0028-4793 ARTICULOS 2026-08-21 sqb 22848 22848